Cargando…

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis

BACKGROUND: Several studies indicate the level of pretreatment lactate dehydrogenase (LDH) may be associated with the prognosis of patients receiving immune checkpoint inhibitors targeting programmed death receptor-1 (PD-1)/programmed death ligand 1 (PD-L1) which had been reported to dramatically im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jun, Zhao, Jianguo, Wang, Jianfang, Sun, Caiping, Zhu, Xiaoling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036123/ https://www.ncbi.nlm.nih.gov/pubmed/33832106 http://dx.doi.org/10.1097/MD.0000000000025318

Ejemplares similares

The co-expression of CBX8 and PD-L1 and prognostic value in cervical cancer
por: Zhou, Hui, et al.
Publicado: (2021)

Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer: A Meta-Analysis
por: Zhang, Yaxiong, et al.
Publicado: (2015)

Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports
por: Lu, Chieh-Sheng, et al.
Publicado: (2017)

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
por: Hao, Chunyan, et al.
Publicado: (2017)

Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis
por: Wang, Qianqian, et al.
Publicado: (2017)

Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report
por: Wang, Junhui, et al.
Publicado: (2023)

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
por: Zhao, Yanjie, et al.
Publicado: (2020)

The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy
por: Liu, Xiaofan, et al.
Publicado: (2017)

Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials
por: Zhou, Guo-Wu, et al.
Publicado: (2016)

Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis
por: Zheng, Zheng, et al.
Publicado: (2020)

Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report
por: Yamaguchi, Kyoko, et al.
Publicado: (2021)

Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report
por: Inadomi, Kyoko, et al.
Publicado: (2016)

Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma
por: Ji, Fei, et al.
Publicado: (2016)

Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials
por: Zhu, Peng, et al.
Publicado: (2021)

A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
por: Wang, Cuihua, et al.
Publicado: (2016)

Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors
por: Li, Lingling, et al.
Publicado: (2021)

The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis
por: Lan, Bo, et al.
Publicado: (2021)

The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis
por: Wu, Lin-guang-jin, et al.
Publicado: (2021)

PD-L1 – inhibitors in neuroendocrine neoplasia: Results from a real-life study
por: Özdirik, Burcin, et al.
Publicado: (2021)

A real-world study of recombinant human endostatin combined with PD-1/PD-L1 blockade and chemotherapy for patients with advanced non-small cell lung cancer negative for actionable molecular biomarkers
por: Zhao, Jing-Wen, et al.
Publicado: (2023)

Pretreatment elevated serum lactate dehydrogenase as a significant prognostic factor in malignant mesothelioma: A meta-analysis
por: Zhuo, Yi, et al.
Publicado: (2016)

Prognostic significance of volume-based (18)F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma
por: Wang, Dalong, et al.
Publicado: (2021)

Primary pleural epithelioid angiosarcoma treated successfully with anti-PD-1 therapy: A rare case report
por: Wang, Xia, et al.
Publicado: (2021)

Prognostic significance of pretreated serum lactate dehydrogenase level in nasopharyngeal carcinoma among Chinese population: A meta-analysis
por: Zhang, Mingwei, et al.
Publicado: (2016)

Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report
por: Luo, Yi, et al.
Publicado: (2021)

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
por: Diem, S, et al.
Publicado: (2016)

Adverse reactions and efficacy of camrelizumab in patients with lung adenocarcinoma with high PD-L1 expression: A case report
por: Wei, Tingting, et al.
Publicado: (2023)

Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis
por: Xian, Feng, et al.
Publicado: (2023)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Expression and prognostic value of AIM1L in esophageal squamous cell carcinoma
por: Zhou, Lu, et al.
Publicado: (2023)

Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report
por: Fricke, Jeremy, et al.
Publicado: (2020)

Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study
por: Yang, Jia, et al.
Publicado: (2019)

Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy
por: Shin, Kabsoo, et al.
Publicado: (2023)

A high density of PD-L1-expressing immune cells is significantly correlated with favorable disease free survival in nonmetastatic colorectal cancer
por: Kuo, Ya-Ting, et al.
Publicado: (2022)

The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
por: Zhang, Qianning, et al.
Publicado: (2022)

Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report
por: Misir Krpan, Ana, et al.
Publicado: (2020)

Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC)
por: Ma, Fei, et al.
Publicado: (2017)

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
por: Ascierto, Paolo A., et al.
Publicado: (2015)

Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma
por: Daneshmandi, Saeed, et al.
Publicado: (2019)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sjf3obk8lclq6f8rd8jjh1h368